Combination of Dual Serum Fluorescence, AFP and Hepatic Function Tests is Valuable to Identify HCC in AFP-elevated Liver Diseases

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 13

PMID 29228649

Citations 10

Authors

Ting Wang

Kun-He Zhang

Piao-Ping Hu

Qin-Si Wan

Fang-Li Han

Jian-Ming Zhou

De-Qiang Huang

Nong-Hua Lv

Affiliations

Soon will be listed here.

Abstract

Serum alpha-fetoprotein (AFP) levels elevated in benign liver diseases (BLD) represent a challenge in hepatocellular carcinoma (HCC) diagnosis. The present study aimed to develop a simple method to identify HCC in AFP-elevated liver diseases based on combining serum fluorescence and general clinical data. Serum specimens and clinical data were collected from 201 HCC and 117 BLD (41 liver cirrhosis, 76 chronic hepatitis) patients with abnormal serum AFP levels. Dual serum fluorescence (autofluorescence and cell-free DNA-related fluorescence) intensities were sequentially measured and expressed as 6 fluorescence indicators. The diagnostic value of these fluorescence and clinical data were evaluated alone and in combination by the area under receiver operating characteristic curve (AUROC). All fluorescence indicators significantly differed between HCC and BLD and some of them were more valuable for diagnosing HCC than AFP (AUROC 0.782-0.801 vs. 0.752). The diagnostic model established with fluorescence indicators, AFP, hepatic function tests and age showed that AUROC, sensitivity, specificity and accuracy were 0.958 (95% CI 0.936-0.979), 92.0%, 88.9% and 92.3%, respectively, and positive rates in AFP-negative, early and small HCCs were 73.8%, 81.6% and 74.3%, respectively. In conclusion, the combination of dual serum fluorescence, AFP, hepatic function tests and age is simple and valuable for identifying HCC in serum AFP-elevated liver diseases.

Citing Articles

Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma.

Liver Res. 2025; 6(2):66-71.

PMID: 39958624 PMC: 11791851. DOI: 10.1016/j.livres.2022.04.001.

The role of novel adipokines in hepatocellular carcinoma progression: a mini review.

Hu P, Guo D, Cao K, Xu T Am J Cancer Res. 2024; 14(11):5471-5485.

PMID: 39659942 PMC: 11626281. DOI: 10.62347/PZDM1736.

A Fast-Response AIE-Active Ratiometric Fluorescent Probe for the Detection of Carboxylesterase.

Xia M, Li C, Liu L, He Y, Li Y, Jiang G Biosensors (Basel). 2022; 12(7).

PMID: 35884287 PMC: 9313056. DOI: 10.3390/bios12070484.

Aptamer-Based Triple Serum Fluorescence Intensity Assay: A Novel and Feasible Method for the Clinical Diagnosis of Primary Hepatic Carcinoma.

Zhou J, Han F, Zhang H, Sun Y, Li Z, Wang T Front Oncol. 2022; 12:897775.

PMID: 35747812 PMC: 9210211. DOI: 10.3389/fonc.2022.897775.

Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges.

Wang J, Wang X, Zhang X, Shao T, Luo Y, Wang W Front Oncol. 2022; 12:884369.

PMID: 35692794 PMC: 9175035. DOI: 10.3389/fonc.2022.884369.

References

Chen K, Zhang H, Zhang L, Ju S, Qi J, Huang D . Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol. 2013; 19(20):3143-9. PMC: 3662956. DOI: 10.3748/wjg.v19.i20.3143. View

Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso J . Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2007; 47(1):97-104. DOI: 10.1002/hep.21966. View

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

Lamola A, Russo M . Fluorescence excitation spectrum of bilirubin in blood: a model for the action spectrum for phototherapy of neonatal jaundice. Photochem Photobiol. 2013; 90(2):294-6. PMC: 3940690. DOI: 10.1111/php.12167. View

Di Bisceglie A, Sterling R, Chung R, Everhart J, Dienstag J, Bonkovsky H . Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005; 43(3):434-41. DOI: 10.1016/j.jhep.2005.03.019. View

Lee H, Chung Y, Kim C . Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology. 1991; 14(1):68-72. DOI: 10.1002/hep.1840140112. View

Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S . The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016; 54(12):1296-1305. DOI: 10.1055/s-0042-119529. View

Qin Q, Weng J, Xu G, Chen C, Jia C . Combination of serum tumor markers dickkopf-1, DCP and AFP for the diagnosis of primary hepatocellular carcinoma. Asian Pac J Trop Med. 2017; 10(4):409-413. DOI: 10.1016/j.apjtm.2017.03.016. View

Caviglia G, Abate M, Gaia S, Petrini E, Bosco C, Olivero A . Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Med. 2017; 59(4):283-289. DOI: 10.23736/S0031-0808.17.03353-5. View

10.

Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M . Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res. 2007; 26(6C):4713-9. View

11.

Lim T, Kim D, Han K, Kim H, Shin S, Jung K . Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2015; 51(3):344-53. DOI: 10.3109/00365521.2015.1082190. View

12.

Wong R, Ahmed A, Gish R . Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015; 19(2):309-23. DOI: 10.1016/j.cld.2015.01.005. View

13.

Chen Q, Cheng C, Chen H, Ning Z, Tang S, Zhang X . Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml--a study based on 4,312 patients. PLoS One. 2014; 9(8):e101536. PMC: 4149350. DOI: 10.1371/journal.pone.0101536. View

14.

Khalili K, Kim T, Jang H, Haider M, Khan L, Guindi M . Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol. 2010; 54(4):723-8. DOI: 10.1016/j.jhep.2010.07.025. View

15.

Wang T, Zhang K, Hu P, Huang Z, Zhang P, Wan Q . Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget. 2016; 7(39):64053-64070. PMC: 5325425. DOI: 10.18632/oncotarget.11771. View

16.

Shen Y, Tsai M, Chen S, Leung Y, Hsieh C, Chen Y . Imaging Endogenous Bilirubins with Two-Photon Fluorescence of Bilirubin Dimers. Anal Chem. 2015; 87(15):7575-82. DOI: 10.1021/acs.analchem.5b01903. View

17.

Li X, Guo X, Wang D, Wang Y, Li X, Lei M . Study of method and system for diagnosis of cancer using autofluorescence and Raman spectroscopy. Conf Proc IEEE Eng Med Biol Soc. 2007; 2005:5453-6. DOI: 10.1109/IEMBS.2005.1615717. View

18.

Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T . Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015; 21(37):10573-83. PMC: 4588079. DOI: 10.3748/wjg.v21.i37.10573. View

19.

Liao W, Mao Y, Ge P, Yang H, Xu H, Lu X . Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2015; 94(14):e722. PMC: 4554041. DOI: 10.1097/MD.0000000000000722. View

20.

Zhang Y, Li T, Qiu Y, Zhang T, Guo P, Ma X . Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma. Medicine (Baltimore). 2017; 96(2):e5642. PMC: 5266158. DOI: 10.1097/MD.0000000000005642. View